Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.0034 USD
Change Today -0.0006 / -15.00%
Volume 2.3M
VNTH On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 09/2/15 All times are local (Market data is delayed by at least 15 minutes).

vantage mhealthcare inc (VNTH) Key Developments

Vantage Health Inc. has Changed its Name to Vantage mHealthcare, Inc

Vantage Health Inc. changed its name to Vantage mHealthcare, Inc.

Vantage mHealthcare, Inc. Amends Certificate of Incorporation and Adopts Amended and Restated Bylaws; Moves its Corporate Headquarters to New York

Vantage mHealthcare Inc. has amended its Certificate of Incorporation such that it is now a Delaware corporation and it increased its authorized shares outstanding from 250,000,000 to 500,000,000 shares and reclassified such capital stock into 450,000,000 shares of common stock, par value $0.001, and 50,000,000 shares of preferred stock, par value $0.001. The company has also adopted Amended and Restated Bylaws which, along with the amended Certificate of Incorporation, contain customary public company provisions. The company has officially moved its corporate headquarters to New York, New York, while continuing operational headquarters in Mountain View, CA.

Vantage Health Inc. Provides Update on Scientific Developments

Vantage Health Inc. announced scientific updates. Over the last three months Vantage, and its parent company, has been developing version 2.0 of its sensor technology. Version 2.0 operates on a Bluetooth platform eliminating the need for physical connections to multiple smartphone platforms. The new sensor is wirelessly compatible with all devices that have Bluetooth capability and will also operate with tablet technology. Version 2.0 of the sensor has the capacity to be scaled up to 256 sensor channels. The molecular samples analyzed by the Vantage Sensor 2.0 were sent to a third party laboratory specializing in analytical, environmental and pharmacological testing. When testing for lower and higher concentrations of certain molecules, which are important biomarkers in disease detection, results suggested that the sensor may actually be more sensitive than Gas Chromatography--Mass Spectrometry (GC-MS). A GC-MS is considered the gold standard for molecular analysis typically costing as much as six figures. Vantage plans to retail this sensor for less than $200. A provisional patent was filed recently to protect the proprietary algorithm used to convert the nano-sensor data into useful calibrated measurements. The key inventor, formerly a NASA contractor, has been engaged to help imbed the algorithm into hand-held apps that communicate directly with the new Bluetooth device. The Company also recruited two additional staff members; a Chief Scientist for Nanotechnology who brings 10 years of experience and a Chief Technology Officer who brings 16 years of experience. The company and its partners have just completed version 3.0 of a breath capture device, which attaches directly onto the sensor. The breath capture device allows for unlimited use of the sensor without the risk of contamination between patients and also includes a filtering mechanism, removing water vapor in the breath, which could otherwise interfere with the molecular analysis. The parent company will be filing another provisional patent for this technology as well.

Vantage Health Inc. Auditor Raises 'Going Concern' Doubt

Vantage Health Inc. filed its 10-K on Oct 14, 2014 for the period ending Jun 30, 2014. In this report its auditor, Malone & Bailey, PLLC, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Vantage Health Inc. Appoints Tony Van Bijleveld as an Independent Member of Board of Directors

Vantage Health has appointed Tony van Bijleveld as an independent member of the Board of Directors of company. Van Bijleveld is currently General Manager with drug manufacturer Patheon/DPX. Over the past 30 years he has served in a variety of senior executive capacities in the pharmaceutical and biotech industry including: Managing Director of United Drug PLC, President/General Manager Russia for Schering Plough/MSD, SVP of Organon Biosciences, and Managing Director of KCL Foundation Labs.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VNTH:US $0.00 USD -0.0006

VNTH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VNTH.
View Industry Companies
 

Industry Analysis

VNTH

Industry Average

Valuation VNTH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VANTAGE MHEALTHCARE INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.